PKTX · ProtoKinetix, Inc. · Financials
$0.00
At close · Oct 14
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 3, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit of $48,621,796 and a working capital deficiency of $183,266 at December 31, 2025. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Sep 3, 2026
Market Cap
$82,326
Shares
411.63M
Volume · Oct 14
160K
Avg daily vol (17 sessions)
87.84K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2014
Net Income
-$393.65K
-8.1%
FY2025
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$135.38K
+39.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| — | $106.61K | $99.63K | $112.44K | $448.87K | $435.87K | $527.29K | $369.52K | $337.07K | $296.52K | $450.9K | $158.89K | $13.75K | $74.5K | $0 | $117.42K | $161.51K | — | — | — | — | — | — | — | — | — | |
| — | $58.14K | $61.47K | $99.62K | $162.75K | $317K | $208.97K | $280.44K | $78.07K | $105.26K | $99.65K | $126.77K | $141.5K | $95.75K | $119.4K | $200.99K | $213.03K | — | — | — | — | — | — | — | — | — | |
| — | $51.29K | $52.87K | $48.26K | $58.45K | $3000 | $3000 | $3000 | $3000 | $3000 | $3000 | $1500 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $393.65K | $364.19K | $415.48K | $1.91M | $2.33M | $7.64M | $4.2M | $1.22M | $1.51M | $1.52M | $1.26M | $418.6K | $448.58K | $197.12K | $916.93K | $1.4M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$197.12K | -$916.93K | -$1.4M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $0 | $306 | $1657 | $12 | $3968 | $34.42K | $26.4K | $24K | $12K | $24K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$197.12K | -$1.23M | — | — | — | — | — | — | — | — | — | — | |
| -$445.11K | — | — | — | — | — | — | — | — | — | — | — | — | -$448.58K | -$197.12K | -$1.23M | -$1.39M | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$393.65K | -$364.19K | -$415.48K | -$1.91M | -$2.33M | -$7.64M | -$4.2M | -$1.22M | -$1.51M | -$1.52M | -$1.25M | -$168.48K | -$448.58K | -$197.12K | -$1.23M | -$1.39M | -$1.27M | -$1.55M | -$2.73M | -$1.97M | -$4.83M | -$6.37M | -$3.66M | -$14.88K | -$16.9K | |
| — | — | — | -$415.48K | -$1.91M | -$2.33M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | $0.00 | $0.00 | -$0.01 | -$0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | $0.00 | $0.00 | -$0.01 | -$0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 386.28M | 358.56M | 333.1M | 307.39M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 386.28M | 358.56M | 333.1M | 307.39M | 291.87M | 278.6M | 268.98M | 256.22M | 246.6M | 221.61M | 197.98M | 172.4M | 137.11M | 129.22M | 93.59M | 75.47M | — | — | — | — | — | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.00×
EV/EBIT
—
Biotechnology median 22.06×
P/E (TTM)
—
Biotechnology median 17.66×